Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01108848 · ClinicalTrials.gov registry record
Patient Registry Study of Berinert® in Normal Clinical Practice
A clinical trial, sponsored by CSL Behring.
- Completed
- Registry status
- 318
- Enrollment target
NCT01108848 is a clinical trial that has completed, run by CSL Behring. The registered enrollment target is 318 participants.
The verdict
NCT01108848 has completed, sponsored by CSL Behring.
- COMPLETED
- Registry status
- 318 participants
- Enrollment target
Study Summary
The objective of this patient registry is to collect data on the safety of Berinert® in normal clinical practice in the United States. The patient registry will be maintained for a period of at least 3 years. The duration of individual patient participation will vary and is determined by the frequency of hereditary angioedema (HAE) attacks and the patient's need for Berinert® treatment.
Interventions
- BIOLOGICAL Berinert® (C1 Esterase Inhibitor)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 318 participants |
| Start Date | 2010-04 |
| Est. Completion | 2014-04 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01108848
The ClinicalTrials.gov registry entry for NCT01108848 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 318 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CSL Behring, which has 71 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Berinert® (C1 Esterase Inhibitor) is the first listed.
NCT01108848 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01108848 about?
NCT01108848 is a clinical study titled "Patient Registry Study of Berinert® in Normal Clinical Practice". The objective of this patient registry is to collect data on the safety of Berinert® in normal clinical practice in the United States. The patient registry will be maintained for a period of at least 3 years. The duration of individual patient participation will vary and is determined by the frequen...
What is the current status of trial NCT01108848?
This trial is currently completed. The enrollment target is 318 participants. The study started on 2010-04. Estimated completion is 2014-04.
What interventions are being tested in trial NCT01108848?
The interventions under investigation include: Berinert® (C1 Esterase Inhibitor) (BIOLOGICAL).
Who is sponsoring clinical trial NCT01108848?
This trial is sponsored by CSL Behring, which has 71 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.